Clinical and Molecular Findings After Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data
Lynette Keyes‐Elstein(Rho (United States)), Keith M. Sullivan(Duke Medical Center), George E. Georges(Northwestern University), E. William St. Clair(Duke University), Maureen D. Mayes(The University of Texas Health Science Center), Mary Ellen Csuka(Medical College of Wisconsin), Jennifer M. Franks(Dartmouth College), Daniel E. Furst(University of California, Los Angeles), Richard A. Nash(Colorado Blood Cancer Institute), Leslie J. Crofford(Vanderbilt University Medical Center), Dinesh Khanna(University of Michigan), Tammara Wood(Dartmouth College), Robert W. Simms(Dartmouth–Hitchcock Medical Center), Michael L. Whitfield(Dartmouth–Hitchcock Medical Center), Peter A. McSweeney(Mesoblast (United States)), Beverly Welch(National Institute of Allergy and Infectious Diseases), Viktor Martyanov(Dartmouth College), Ellen Goldmuntz(National Institute of Allergy and Infectious Diseases), Ashley Pinckney(National Institute of Allergy and Infectious Diseases)
Cited by 11
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k